- Home
- RDHL vs OGEN Comparison
RDHL vs OGEN Comparison
Compare RDHL & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- OGEN
- Stock Information
- Founded
- RDHL 2009
- OGEN 1996
- Country
- RDHL Israel
- OGEN United States
- Employees
- RDHL N/A
- OGEN N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- OGEN Health Care
- Exchange
- RDHL Nasdaq
- OGEN Nasdaq
- Market Cap
- RDHL 3.8M
- OGEN 4.6M
- IPO Year
- RDHL N/A
- OGEN N/A
- Fundamental
- Price
- RDHL $1.99
- OGEN $4.28
- Analyst Decision
- RDHL
- OGEN
- Analyst Count
- RDHL 0
- OGEN 0
- Target Price
- RDHL N/A
- OGEN N/A
- AVG Volume (30 Days)
- RDHL 214.4K
- OGEN 599.0K
- Earning Date
- RDHL 04-10-2025
- OGEN 05-09-2025
- Dividend Yield
- RDHL N/A
- OGEN N/A
- EPS Growth
- RDHL N/A
- OGEN N/A
- EPS
- RDHL N/A
- OGEN N/A
- Revenue
- RDHL $8,042,999.00
- OGEN N/A
- Revenue This Year
- RDHL $381.91
- OGEN N/A
- Revenue Next Year
- RDHL N/A
- OGEN N/A
- P/E Ratio
- RDHL N/A
- OGEN N/A
- Revenue Growth
- RDHL 23.17
- OGEN N/A
- 52 Week Low
- RDHL $1.71
- OGEN $3.12
- 52 Week High
- RDHL $20.28
- OGEN $75.60
- Technical
- Relative Strength Index (RSI)
- RDHL 51.03
- OGEN 43.10
- Support Level
- RDHL $1.82
- OGEN $3.12
- Resistance Level
- RDHL $1.93
- OGEN $9.60
- Average True Range (ATR)
- RDHL 0.08
- OGEN 1.04
- MACD
- RDHL 0.04
- OGEN -0.12
- Stochastic Oscillator
- RDHL 100.00
- OGEN 17.90
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.